Stephan Dietrich A 4
4 · NeuBase Therapeutics, Inc. · Filed Jul 16, 2019
Insider Transaction Report
Form 4
Stephan Dietrich A
DirectorPresident and CEO10% Owner
Transactions
- Award
Stock option (right to buy)
2019-07-12+3,311,930→ 3,311,930 totalExercise: $0.00From: 2019-07-12Exp: 2028-12-31→ Common stock (3,311,930 underlying) - Award
Common stock
2019-07-12+2,547,639→ 2,547,639 total(indirect: See footnote)
Footnotes (3)
- [F1]Shares of common stock of the corporation formerly known as NeuBase Therapeutics, Inc. ("NeuBase") were converted into shares of common stock of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization (the "Merger"), dated as of January 2, 2019, by and among the Issuer, Ohr Acquisition Corp., and NeuBase, as amended (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of NeuBase common stock was exchanged for 1.019055643 shares of the Issuer's common stock. Immediately following the merger, the Issuer changed its name to NeuBase Therapeutics, Inc.
- [F2]Shares held directly by Lipizzaner LLC, of which Dr. Stephan is the sole member.
- [F3]Received in the Merger in exchange for an employee stock option to acquire 3,250,000 shares of Issuer common stock for $0.001 per share.